C4J Stock Overview
C4X Discovery Holdings plc operates as drug discovery company in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
C4X Discovery Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.12 |
| 52 Week High | €0.30 |
| 52 Week Low | €0.059 |
| Beta | 0.23 |
| 11 Month Change | 30.34% |
| 3 Month Change | -12.12% |
| 1 Year Change | -17.14% |
| 33 Year Change | -74.78% |
| 5 Year Change | n/a |
| Change since IPO | -34.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| C4J | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 63.4% | 3.9% | 0.8% |
| 1Y | -17.1% | 5.4% | 9.1% |
Return vs Industry: C4J underperformed the German Life Sciences industry which returned -10.6% over the past year.
Return vs Market: C4J underperformed the German Market which returned 2% over the past year.
Price Volatility
| C4J volatility | |
|---|---|
| C4J Average Weekly Movement | 21.9% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: C4J's share price has been volatile over the past 3 months.
Volatility Over Time: C4J's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 49 | Clive Dix | www.c4xdiscovery.com |
C4X Discovery Holdings plc operates as drug discovery company in the United Kingdom. The company provides Taxonomy3, a novel in silico platform technology that utilizes proprietary mathematical algorithms to perform complex multivariate analysis of genetic data; Conformetrix, a technology platform which allows 3D-shapes of free drug molecules to be measured from experimental data, giving medicinal chemists new and unprecedented insights into the behavior and physical properties of drug molecules; and 4Sight for visualizing 4D molecules in virtual reality research scientists to view, understand and interrogate the complex, multidimensional molecular shape data of drug molecules. Its product pipeline includes Orexin-1, a receptor antagonist for the treatment of addictive disorders; NRF-2 activator to treat various inflammatory diseases; IL-17A inhibitor for inflammation diseases; a4ß7 integrin inhibitors for the treatment of inflammatory bowel disease; and MALT-1 inhibitors to treat hematological cancer.
C4X Discovery Holdings plc Fundamentals Summary
| C4J fundamental statistics | |
|---|---|
| Market cap | €30.27m |
| Earnings (TTM) | €12.34m |
| Revenue (TTM) | €28.83m |
2.4x
P/E Ratio1.0x
P/S RatioIs C4J overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| C4J income statement (TTM) | |
|---|---|
| Revenue | UK£24.68m |
| Cost of Revenue | UK£16.00k |
| Gross Profit | UK£24.66m |
| Other Expenses | UK£14.10m |
| Earnings | UK£10.57m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.042 |
| Gross Margin | 99.94% |
| Net Profit Margin | 42.81% |
| Debt/Equity Ratio | 0% |
How did C4J perform over the long term?
See historical performance and comparison